The estimated Net Worth of Gary A Lyons is at least $29.1 Millón dollars as of 13 August 2024. Mr. Lyons owns over 11,570 units of Neurocrine Biosciences stock worth over $15,866,047 and over the last 22 years he sold NBIX stock worth over $12,764,369. In addition, he makes $507,100 as Independent Director at Neurocrine Biosciences.
Gary has made over 41 trades of the Neurocrine Biosciences stock since 2010, according to the Form 4 filled with the SEC. Most recently he exercised 11,570 units of NBIX stock worth $494,733 on 13 August 2024.
The largest trade he's ever made was exercising 85,000 units of Neurocrine Biosciences stock on 7 March 2014 worth over $933,300. On average, Gary trades about 3,198 units every 36 days since 2003. As of 13 August 2024 he still owns at least 130,617 units of Neurocrine Biosciences stock.
You can see the complete history of Mr. Lyons stock trades at the bottom of the page.
Gary A. Lyons serves as Independent Director of the Company. He has served on the Board of Directors since joining Neurocrine Biosciences in February 1993. Mr. Lyons served as the President and Chief Executive Officer of the Company from February 1993 through January 2008. Prior to joining the Company, Mr. Lyons held a number of senior management positions at Genentech, Inc., including Vice President of Business Development and Vice President of Sales. Mr. Lyons is currently the Chairman of the Board of Directors for each of Rigel Pharmaceuticals, Inc., a biotechnology company focused on developing drugs for the treatment of inflammatory/autoimmune and metabolic diseases, and Retrophin, an ultra-orphan disease commercial stage company. Mr. Lyons is a member of the Board of Directors of Brickell Biotech, Inc., a biotechnology company focused on dermatology, and Novus Therapeutics, Inc., a biotechnology company focused on ear, nose and throat therapies. Mr. Lyons was previously a director of Neurogesx, Cytori Therapeutics, and Facet Biotech Corporation. Mr. Lyons holds a B.S. in marine biology from the University of New Hampshire and an M.B.A. from Northwestern University’s J.L. Kellogg Graduate School of Management. The continued service of Mr. Lyons on the Company’s Board of Directors is based on Mr. Lyons’ extensive business development and corporate governance experience and, as the Company’s former Chief Executive Officer, his in-depth understanding of the Company’s product candidates, management and culture. With this history with the Company and management, Mr. Lyons brings a unique perspective and point of view to the Company’s Board of Directors.
As the Independent Director of Neurocrine Biosciences, the total compensation of Gary Lyons at Neurocrine Biosciences is $507,100. There are 17 executives at Neurocrine Biosciences getting paid more, with Kevin Gorman having the highest compensation of $9,450,830.
Gary Lyons is 68, he's been the Independent Director of Neurocrine Biosciences since 2008. There are 1 older and 22 younger executives at Neurocrine Biosciences. The oldest executive at Neurocrine Biosciences, Inc. is William Rastetter, 72, who is the Independent Chairman of the Board.
Gary's mailing address filed with the SEC is 12780, El Camino Real, San Diego, San Diego County, California, 92014, United States.
Over the last 22 years, insiders at Neurocrine Biosciences have traded over $159,913,426 worth of Neurocrine Biosciences stock and bought 103,400 units worth $589,660 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Partners L P/Ilbiotechnolog... y Richard F Pops. On average, Neurocrine Biosciences executives and independent directors trade stock every 8 days with the average trade being worth of $1,567,813. The most recent stock trade was executed by William H Rastetter on 15 August 2024, trading 14,250 units of NBIX stock currently worth $2,090,333.
neurocrine biosciences, inc of san diego is a product based biopharmaceutical company focusing on the development and commercialization of innovative pharmaceutical products to treat unmet medical needs. the company's research and development efforts are focused on neurological and endocrine diseases and disorders. our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, irritable bowel syndrome, anxiety, depression, pain, diabetes, insomnia, and other neurological and endocrine related diseases and disorders
Neurocrine Biosciences executives and other stock owners filed with the SEC include: